BE2016C033I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C033I2
BE2016C033I2 BE2016C033C BE2016C033C BE2016C033I2 BE 2016C033 I2 BE2016C033 I2 BE 2016C033I2 BE 2016C033 C BE2016C033 C BE 2016C033C BE 2016C033 C BE2016C033 C BE 2016C033C BE 2016C033 I2 BE2016C033 I2 BE 2016C033I2
Authority
BE
Belgium
Prior art keywords
hsv1
strain
hsv
tumour cells
oncolytic
Prior art date
Application number
BE2016C033C
Other languages
French (fr)
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27447756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C033(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0001475A external-priority patent/GB0001475D0/en
Priority claimed from GB0002854A external-priority patent/GB0002854D0/en
Priority claimed from GB0100288A external-priority patent/GB0100288D0/en
Priority claimed from GB0100430A external-priority patent/GB0100430D0/en
Application filed by Biovex Ltd filed Critical Biovex Ltd
Publication of BE2016C033I2 publication Critical patent/BE2016C033I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of a modified, oncolytic, herpes simplex virus (HSV) strain in the manufacture of a medicament for the oncolytic treatment of cancer, which HSV strain: (a) has a greater ability than HSV1 17+, HSV1 F and HSV1 KOS strains with equivalent modifications to replicate in or kill tumour cells; and (b) is obtainable by isolating an HSV strain from a host and modifying the isolated HSV strain to provide for selective replication in tumour cells.
BE2016C033C 2000-01-21 2016-06-14 BE2016C033I2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0001475A GB0001475D0 (en) 2000-01-21 2000-01-21 Virus strains
GB0002854A GB0002854D0 (en) 2000-02-08 2000-02-08 Virus strains
GB0100288A GB0100288D0 (en) 2001-01-05 2001-01-05 Virus strains
GB0100430A GB0100430D0 (en) 2001-01-06 2001-01-06 Virus strains
PCT/GB2001/000225 WO2001053505A2 (en) 2000-01-21 2001-01-22 Herpes virus strains for gene therapy

Publications (1)

Publication Number Publication Date
BE2016C033I2 true BE2016C033I2 (en) 2020-05-20

Family

ID=27447756

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C033C BE2016C033I2 (en) 2000-01-21 2016-06-14

Country Status (22)

Country Link
US (12) US7063835B2 (en)
EP (4) EP2177619A1 (en)
JP (6) JP4921669B2 (en)
KR (2) KR100768408B1 (en)
CN (2) CN1250732C (en)
AT (2) ATE282708T1 (en)
AU (2) AU2001226951B8 (en)
BE (1) BE2016C033I2 (en)
BR (3) BR0107736A (en)
CA (2) CA2398343A1 (en)
CY (2) CY2016021I1 (en)
DE (2) DE60107203T3 (en)
DK (2) DK1252322T4 (en)
ES (2) ES2233600T5 (en)
FR (1) FR16C0026I2 (en)
GB (2) GB2375113B (en)
HK (2) HK1047297B (en)
IL (4) IL150677A0 (en)
LU (2) LU93101I2 (en)
NL (2) NL300821I2 (en)
PT (1) PT1252322E (en)
WO (2) WO2001053505A2 (en)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
WO2001053505A2 (en) 2000-01-21 2001-07-26 Biovex Limited Herpes virus strains for gene therapy
JP4212897B2 (en) 2001-03-27 2009-01-21 具紀 藤堂 Viruses and their use in therapy
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (en) 2002-05-02 2004-04-02 Keio Gijuku Anti-tumor agent using HSV
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
WO2005049846A2 (en) * 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
JP5522884B2 (en) * 2004-03-31 2014-06-18 具紀 藤堂 Anti-cancer effect enhancer for viral therapy, cancer prevention or treatment method
WO2005099771A2 (en) * 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
US9273326B2 (en) * 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
CN101287834B (en) * 2005-05-27 2016-11-09 圣拉法埃莱医院有限公司 Gene carrier
US20080008686A1 (en) * 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
HRP20160573T1 (en) 2009-12-21 2016-09-23 The Brigham And Women's Hospital, Inc. Herpes simplex virus vaccines
CN102146418B (en) * 2010-02-09 2014-01-15 武汉滨会生物科技有限公司 Recombinant II type herpes simplex virus vector, preparation method of recombinant II type herpes simplex virus vector, recombinant virus, medicinal composition and application
US8945531B2 (en) * 2010-02-19 2015-02-03 The University Of Tokyo Recombinant herpes virus and pharmaceutical composition containing the same
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US20130202639A1 (en) * 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
EP2753355B1 (en) 2011-09-08 2018-10-24 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
EP2877572B1 (en) 2012-07-24 2018-11-28 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
JP6457940B2 (en) * 2012-08-30 2019-01-23 アムジエン・インコーポレーテツド Method for treating melanoma using herpes simplex virus and immune checkpoint inhibitors
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
KR102382295B1 (en) * 2013-07-17 2022-04-04 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production
JP7051293B2 (en) 2013-10-24 2022-04-11 アムジエン・インコーポレーテツド Drug delivery system with temperature sensing control
BR112016008946B1 (en) 2013-10-24 2022-12-27 Amgen Inc INJECTORS AND METHOD FOR ASSEMBLING THE INJECTORS
DK3021859T3 (en) 2013-10-25 2018-03-05 Psioxus Therapeutics Ltd ONCOLYTIC ADENOVIRA EQUIPPED WITH HETEROLOGICAL GENES
EP3082834B1 (en) 2013-12-11 2020-03-11 The General Hospital Corporation DBA Massachusetts Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
MA39818A (en) 2014-03-30 2017-02-08 Benevir Biopharm Inc Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof
MX388536B (en) 2014-05-07 2025-03-20 Amgen Inc AUTO-INJECTOR WITH SHOCK-REDUCING ELEMENTS.
CN106470717B (en) 2014-06-03 2020-09-11 安姆根有限公司 Drug delivery system and method of use
MX2021014323A (en) 2014-10-14 2023-02-02 Amgen Inc Drug injection device with visual and audio indicators.
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
JP6716566B2 (en) 2014-12-19 2020-07-01 アムジエン・インコーポレーテツド Drug delivery device with proximity sensor
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
CA2970954C (en) 2015-01-26 2023-10-31 Ottawa Hospital Research Institute Compositions and methods for viral sensitization
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (en) 2015-02-27 2022-04-13 Amgen, Inc Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
GB201505860D0 (en) 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
HUE048320T2 (en) * 2015-04-30 2020-07-28 Psioxus Therapeutics Ltd Oncolytic adenovirus encoding a b7 protein
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
CN105219738A (en) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 Recombinant herpes simplex virus and its infect and prepare its host cell and their application
KR20180104597A (en) 2015-11-07 2018-09-21 멀티비르 인코포레이티드 Compositions comprising tumor suppressor gene therapy and immune blockade for cancer therapy
JP7082568B2 (en) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド Automatic syringe with signal transduction cap
AU2016369485B2 (en) 2015-12-17 2024-02-01 Akamis Bio Limited Group B adenovirus encoding an anti-TCR-complex antibody or fragment
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
CN109415703B (en) 2016-01-08 2024-08-30 雷普利穆内有限公司 Modified oncolytic viruses
US20190307820A1 (en) 2016-02-19 2019-10-10 Virogin Biotech Canada Ltd Compositions and methods of using stat1/3 inhibitors with oncolytic herpes virus
EP4035711B1 (en) 2016-03-15 2025-06-04 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017165813A1 (en) 2016-03-25 2017-09-28 Periphagen, Inc. High-transducing hsv vectors
KR20250095754A (en) 2016-04-15 2025-06-26 알파인 이뮨 사이언시즈, 인코포레이티드 Icos ligand variant immunomodulatory proteins and uses thereof
MA43552A (en) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc CD80 VARIANT IMMUNOMODULATOR PROTEINS AND THEIR USES
WO2017189754A1 (en) * 2016-04-26 2017-11-02 Salk Institute For Biological Studies Hsv--1 oncolytic virus therapies that specificallyh kill alt dependent cancers
EP3448401B1 (en) 2016-04-29 2021-10-27 Virogin Biotech Canada Ltd Hsv vectors with enhanced replication in cancer cells
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (en) 2016-05-13 2019-02-21 Amgen Inc Vial sleeve assembly.
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US12162919B2 (en) 2016-08-01 2024-12-10 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
JP2019532621A (en) 2016-08-29 2019-11-14 サイオクサス セラピューティクス リミテッド Adenovirus armed with a bispecific T cell engager (BiTE)
US11517598B2 (en) 2016-10-03 2022-12-06 Ottawa Hospital Research Institute Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic RNA viruses
WO2018075447A1 (en) 2016-10-19 2018-04-26 The Trustees Of Columbia University In The City Of New York Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
US20200040059A1 (en) 2016-10-20 2020-02-06 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
JP2020510624A (en) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド Methods and compositions comprising viral gene therapy and immune checkpoint inhibitors for the treatment and prevention of cancer and infectious diseases
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
WO2018118967A1 (en) 2016-12-21 2018-06-28 Memgen, Llc Armed replication-competent oncolytic adenoviruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
JP2020503976A (en) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド Injection device and associated methods of use and assembly
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
US20200024615A1 (en) * 2018-07-21 2020-01-23 Richard Postrel Method for Precise Identification, Targeting and Delivery of Directed Therapies for Destruction of Cancerous Cells
JP2020508803A (en) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド Drug delivery device with anti-actuation feature
SG11201908058UA (en) 2017-03-07 2019-09-27 Amgen Inc Needle insertion by overpressure
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for a drug delivery device
EP3595690A1 (en) 2017-03-15 2020-01-22 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
HRP20231382T1 (en) 2017-03-16 2024-02-16 Alpine Immune Sciences, Inc. PD-L1 VARIANT OF IMMUNOMODULATING PROTEINS AND THEIR USE
KR20190141146A (en) 2017-03-16 2019-12-23 알파인 이뮨 사이언시즈, 인코포레이티드 PD-L2 variant immunomodulatory protein and uses thereof
MX2019010887A (en) 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof.
CN114588404B (en) 2017-03-28 2024-07-09 美国安进公司 Plunger rod and syringe assembly system and method
SG11201908296VA (en) 2017-04-28 2019-10-30 Merck Sharp & Dohme Biomarkers for cancer therapeutics
CN106974942A (en) * 2017-05-03 2017-07-25 武汉滨会生物科技股份有限公司 Application of the recombination oncolytic II herpes simplex virus types in anti-lymphadenoma, cancer of the esophagus, breast cancer, pancreatic cancer drug is prepared
EP3634539A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (en) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド Torque driven drug delivery device
CN107354136A (en) * 2017-06-15 2017-11-17 杭州睿可特生物科技有限公司 Recombinant herpes simplex virus and its preparation method and application
MX2019015472A (en) 2017-06-22 2020-02-19 Amgen Inc Device activation impact/shock reduction.
CA3063921A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
ES2972207T3 (en) 2017-07-14 2024-06-11 Amgen Inc Needle insertion-retraction system with double torsion spring system
MA49626A (en) 2017-07-21 2020-05-27 Amgen Inc GAS PERMEABLE SEALING ELEMENT FOR DRUG CONTAINER AND ASSEMBLY PROCEDURES
MA49676A (en) 2017-07-25 2020-06-03 Amgen Inc DRUG ADMINISTRATION DEVICE EQUIPPED WITH A CONTAINER ACCESS SYSTEM AND ASSOCIATED ASSEMBLY PROCEDURE
MA49677A (en) 2017-07-25 2021-04-21 Amgen Inc DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSOCIATED ASSEMBLY PROCESS
MX2020001328A (en) 2017-08-03 2020-03-20 Amgen Inc INTERLEUKIN 21 MUTEINS AND TREATMENT METHODS.
EP3664844A1 (en) 2017-08-07 2020-06-17 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
MA49838A (en) 2017-08-09 2020-06-17 Amgen Inc DRUG DELIVERY SYSTEM WITH CHAMBER HYDRAULIC-PNEUMATIC PRESSURE
MA49897A (en) 2017-08-18 2020-06-24 Amgen Inc ON-BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
CA3075046A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
US20200308550A1 (en) 2017-09-11 2020-10-01 Imba - Institut Für Molekulare Biotechnologie Gmbh Tumor organoid model
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
US11813426B2 (en) 2017-10-06 2023-11-14 Amgen Inc. Drug delivery device including seal member for needle of syringe
MA50348A (en) 2017-10-09 2020-08-19 Amgen Inc DRUG ADMINISTRATION DEVICE INCLUDING A TRAINING ASSEMBLY AND ASSOCIATED ASSEMBLY PROCEDURE
CN111801347A (en) 2017-10-10 2020-10-20 高山免疫科学股份有限公司 CTLA-4 variant immunomodulatory proteins and uses thereof
TW202500579A (en) 2017-10-18 2025-01-01 美商艾爾潘免疫科學有限公司 Variant icos ligand immunomodulatory proteins and related compositions and methods
CA3075294A1 (en) 2017-10-27 2019-05-02 Merck Sharp & Dohme Corp. Compositions and methods for treating liver cancer
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
MX2020004736A (en) 2017-11-10 2020-08-13 Amgen Inc Plungers for drug delivery devices.
EP3710090A1 (en) 2017-11-16 2020-09-23 Amgen Inc. Door latch mechanism for drug delivery device
CA3079100C (en) 2017-11-24 2023-09-19 Ottawa Hospital Research Institute Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
AU2019207895A1 (en) 2018-01-12 2020-06-18 Amgen Inc. Anti-PD-1 antibodies and methods of treatment
US11390650B2 (en) 2018-02-05 2022-07-19 The Brigham And Women's Hospital, Inc. Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
WO2020036635A2 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
WO2019185828A1 (en) * 2018-03-28 2019-10-03 Bioxodes Anticoagulant fusion proteins and uses thereof
US20210236625A1 (en) * 2018-05-01 2021-08-05 Albert Einstein College Of Medicine HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
CN112533621A (en) 2018-06-04 2021-03-19 卡利迪生物治疗有限公司 Cell-based agents for enhancing viral therapy
AU2019282755B2 (en) * 2018-06-08 2025-09-11 The Board Of Trustees Of University Of Illinois Recombinant Herpes Simplex Virus for cancer immunotherapy
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
EP3807304A1 (en) * 2018-06-15 2021-04-21 Children's Hospital Medical Center Polypeptides, nucleic acid molecules, compositions, and related methods
MA53375A (en) 2018-07-24 2021-06-02 Amgen Inc ADMINISTRATION DEVICES FOR THE ADMINISTRATION OF MEDICINES
MA53379A (en) 2018-07-24 2021-06-02 Amgen Inc ADMINISTRATION DEVICES FOR THE ADMINISTRATION OF MEDICINES
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53320A (en) 2018-07-31 2021-11-03 Amgen Inc FLUID PATH ASSEMBLY FOR DRUG DELIVERY DEVICE
CN109161561A (en) * 2018-08-09 2019-01-08 湖北科技学院 A kind of the novel oncolytic virus and its construction method of selectively killing prostate gland cancer cell
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
AU2019350660B2 (en) 2018-09-28 2024-09-26 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
MX2021003492A (en) 2018-10-02 2021-06-18 Amgen Inc INJECTION SYSTEMS FOR THE ADMINISTRATION OF DRUGS WITH TRANSMISSION OF INTERNAL FORCE.
CA3112214A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
KR20250127186A (en) 2018-10-15 2025-08-26 암젠 인크 Drug delivery device having damping mechanism
TWI831847B (en) 2018-11-01 2024-02-11 美商安進公司 Drug delivery devices with partial needle retraction and methods for operating the same
IL281908B2 (en) 2018-11-01 2025-06-01 Amgen Inc Drug delivery devices with partial drug delivery unit withdrawal
MA54048A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY DEVICES WITH PARTIAL RETRACTION OF DRUG DELIVERY BODY
US11655455B2 (en) 2018-11-06 2023-05-23 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
KR20210123289A (en) 2018-11-21 2021-10-13 인답타 세라뷰틱스 인코포레이티드 Methods and related compositions and methods for propagation of natural killer cell subsets
TW202038947A (en) 2018-11-28 2020-11-01 德商創新分子有限責任公司 Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses
JP7713886B2 (en) 2018-11-30 2025-07-28 アルパイン イミューン サイエンシズ インコーポレイテッド CD86 variant immunomodulatory proteins and uses thereof
US12364723B2 (en) 2018-12-27 2025-07-22 Amgen Inc. Thermostable compositions comprising live attenuated herpes simplex virus type 1
EP3921334A1 (en) * 2019-02-08 2021-12-15 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
BR112021016728A2 (en) 2019-02-27 2022-01-11 Actym Therapeutics Inc Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells and the tumor microenvironment
CA3131529A1 (en) 2019-03-05 2020-09-10 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
JP2022526094A (en) * 2019-03-14 2022-05-23 マサチューセッツ インスティテュート オブ テクノロジー Manipulated herpes simplex virus-1 (HSV-1) vector and its use
TW202102543A (en) 2019-03-29 2021-01-16 美商安進公司 Use of oncolytic viruses in the neoadjuvant therapy of cancer
CA3137360A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CA3160199A1 (en) * 2019-12-20 2021-06-24 Suma Krishnan Compositions and methods for gene delivery to the airways and/or lungs
KR20230088306A (en) 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 Natural Killer (NK) Cell Compositions and Methods of Producing The Same
WO2022015407A1 (en) * 2020-07-16 2022-01-20 Massachusetts Institute Of Technology Simultaneous delivery of cancer treatment programs to tumor and immune cells
TW202241479A (en) 2020-12-30 2022-11-01 美商安迅生物製藥公司 Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
IL307418A (en) 2021-05-21 2023-12-01 Amgen Inc Method of optimizing a filling recipe for a drug container
WO2023020598A1 (en) * 2021-08-20 2023-02-23 广东东阳光药业有限公司 Hsv virus vector and use thereof
EP4574169A1 (en) 2022-08-16 2025-06-25 Tomoki Todo Pharmaceutical composition containing herpes simplex virus vector
WO2024251286A1 (en) * 2023-06-08 2024-12-12 上海药明生物医药有限公司 Oncolytic hsv-1 clinical isolate, directed evolution strain, infectious clone and use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5163949A (en) * 1990-03-02 1992-11-17 Bonutti Peter M Fluid operated retractors
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
GB9202933D0 (en) 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
ES2183811T3 (en) 1992-03-31 2003-04-01 Arch Dev Corp TUMORIGENE DISEASE TREATMENT WITH A MODIFIED HSV.
GB9325496D0 (en) 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
GB9423663D0 (en) * 1994-11-23 1995-01-11 Cantab Pharma Res Viral preparations, immunogens, and vaccines
NL9500216A (en) * 1995-02-06 1996-09-02 Bio Pharma Sciences Bv Pharmaceutical composition for the treatment of herpes.
DE69636068T2 (en) * 1995-02-21 2006-11-30 Cantab Pharmaceuticals Research Ltd. VIRAL PREPARATIONS, VECTORS, IMMUNOGENS AND VACCINES
IL118942A (en) 1995-07-27 2002-09-12 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6344445B1 (en) * 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
AU1550797A (en) 1996-01-25 1997-08-20 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5876923A (en) * 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
GB2322130B (en) 1997-02-13 2000-12-20 Secr Defence A vaccine against Simian Herpes B virus
GB9704046D0 (en) 1997-02-27 1997-04-16 Univ Leeds Arrestable therapeutic
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
CA2323067A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
GB9810904D0 (en) 1998-05-20 1998-07-22 Univ London Mutant herpes simplex viruses and uses thereof
US6713067B2 (en) * 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
BR9912671A (en) 1998-08-07 2001-05-02 Univ Washington Immunological antigens for herpes simplex virus and methods for their use
EP1141338A4 (en) * 1998-12-31 2002-09-25 Arch Dev Corp RECOMBINANT HERPES SIMPLEX VIRUS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
EP1190040B1 (en) 1999-06-08 2007-08-22 UAB Research Foundation Herpes simplex virus expressing interleukin-12 gene and and its use for treating cancer
IL131212A0 (en) 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
GB9930419D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
WO2001053505A2 (en) * 2000-01-21 2001-07-26 Biovex Limited Herpes virus strains for gene therapy
GB0001476D0 (en) 2000-01-21 2000-03-15 Neurovex Ltd Herpes virus strains
US7063851B2 (en) * 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
CN109415703B (en) * 2016-01-08 2024-08-30 雷普利穆内有限公司 Modified oncolytic viruses

Also Published As

Publication number Publication date
CN1418255A (en) 2003-05-14
EP1252323B1 (en) 2005-12-07
US8680068B2 (en) 2014-03-25
CY2016020I2 (en) 2016-12-14
HK1047451A1 (en) 2003-02-21
EP1252322B1 (en) 2004-11-17
KR100802403B1 (en) 2008-02-13
AU782659B2 (en) 2005-08-18
JP2019048864A (en) 2019-03-28
US20120164108A1 (en) 2012-06-28
NL300820I2 (en) 2016-11-17
CA2398335A1 (en) 2001-07-26
JP2017132779A (en) 2017-08-03
BRPI0107736B8 (en) 2021-05-25
US20070003571A1 (en) 2007-01-04
EP1252323A2 (en) 2002-10-30
AU2001226951B2 (en) 2006-10-05
US20150232812A1 (en) 2015-08-20
WO2001053505A2 (en) 2001-07-26
CA2398335C (en) 2010-12-07
BR0107737A (en) 2002-11-19
CY2016020I1 (en) 2016-12-14
DK1252323T3 (en) 2006-04-03
HK1047451B (en) 2005-03-18
JP6424145B2 (en) 2018-11-14
DE60107203D1 (en) 2004-12-23
IL150678A (en) 2008-12-29
DE60115600D1 (en) 2006-01-12
FR16C0026I2 (en) 2018-04-27
US7537924B2 (en) 2009-05-26
BRPI0107737B8 (en) 2021-05-25
US20200032218A1 (en) 2020-01-30
KR100768408B1 (en) 2007-10-18
GB2374873C (en) 2011-07-27
IL150677A (en) 2008-12-29
DK1252322T4 (en) 2009-06-08
JP6644378B2 (en) 2020-02-12
WO2001053506A2 (en) 2001-07-26
EP1568779A1 (en) 2005-08-31
EP1252322A2 (en) 2002-10-30
AU2001226951B8 (en) 2006-10-26
GB0219030D0 (en) 2002-09-25
DE60115600T2 (en) 2006-07-20
CN1250732C (en) 2006-04-12
GB2374873B (en) 2004-05-26
DE60107203T3 (en) 2009-07-23
IL150678A0 (en) 2003-02-12
US20120321599A1 (en) 2012-12-20
CN1425073A (en) 2003-06-18
BRPI0107736B1 (en) 2019-12-17
JP2015221813A (en) 2015-12-10
US20030113348A1 (en) 2003-06-19
US20070264282A1 (en) 2007-11-15
ATE282708T1 (en) 2004-12-15
KR20030032913A (en) 2003-04-26
ES2233600T5 (en) 2009-06-22
HK1047297B (en) 2004-10-21
GB2375113B (en) 2004-10-20
US20140154216A1 (en) 2014-06-05
LU93101I2 (en) 2016-08-08
US20200032219A1 (en) 2020-01-30
BRPI0107737B1 (en) 2016-11-16
DE60107203T2 (en) 2005-12-01
JP2003520044A (en) 2003-07-02
US7063835B2 (en) 2006-06-20
WO2001053506A3 (en) 2002-05-23
AU2695101A (en) 2001-07-31
NL300821I2 (en) 2016-10-27
IL150677A0 (en) 2003-02-12
US20090220460A1 (en) 2009-09-03
ES2233600T3 (en) 2005-06-16
EP1252322B2 (en) 2009-03-04
JP2003520789A (en) 2003-07-08
LU93100I2 (en) 2016-08-08
US20030091537A1 (en) 2003-05-15
HK1047297A1 (en) 2003-02-14
CA2398343A1 (en) 2001-07-26
PT1252322E (en) 2005-03-31
ATE312189T1 (en) 2005-12-15
BR0107736A (en) 2002-11-19
JP4921669B2 (en) 2012-04-25
FR16C0026I1 (en) 2016-07-22
US10301600B2 (en) 2019-05-28
US7223593B2 (en) 2007-05-29
GB2375113A (en) 2002-11-06
US20140154215A1 (en) 2014-06-05
ES2254359T3 (en) 2006-06-16
EP2177619A1 (en) 2010-04-21
GB2374873A (en) 2002-10-30
JP4810042B2 (en) 2011-11-09
CY2016021I2 (en) 2016-12-14
US8277818B2 (en) 2012-10-02
KR20020080383A (en) 2002-10-23
GB0219033D0 (en) 2002-09-25
JP2012072156A (en) 2012-04-12
CY2016021I1 (en) 2016-12-14
DK1252322T3 (en) 2005-03-14
WO2001053505A3 (en) 2001-12-27
AU2694701A (en) 2001-07-31

Similar Documents

Publication Publication Date Title
FR16C0026I1 (en)
WO2003082200A3 (en) Potent oncolytic herpes simplex virus for cancer therapy
BR9912671A (en) Immunological antigens for herpes simplex virus and methods for their use
BR0014408A (en) Immunologically significant herpes simplex virus antigens; and methods for identifying and using them
BR9712366A (en) Herpes simplex hsv2 gd2 gene isolated, plasmid comprising the same, and processes to induce an immune response against hsv2 gd2 in an individual, to treat an individual who is infected with hsv, and to prevent an individual from becoming infected with hsv
GR3030385T3 (en) Cytopathic viruses for therapy and prophylaxis of neoplasia
DE69131200D1 (en) Herpes simplex virus vp16 impfstoffe
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
ES2141093T3 (en) EQUINE HERPESVIRUSES (EHV) CONTAINING A foreign DNA, PROCEDURE FOR THEIR OBTAINING AND USE IN VACCINES.
GB2359083A (en) Mutant herpes simplex viruses and uses thereof
EP1550449A4 (en) Antitumor agents with the use of hsv
ES2169040T3 (en) RESISTANT PLANT TO TWO OR MORE VIRUSES AND PREPARATION OF THE SAME.
WO2003045428A3 (en) Use of a technically modified cell as a vaccine for treating tumoral disease
AU630099B2 (en) Non-reverting rna viruses
AU6751794A (en) Extracts of piliostigma thonningii, the use thereof and formulations containing them
Horstmann et al. Modified indication for surgery in AIDS associated gastrointestinal lymphomas
Saran et al. Palliative treatment of AIDS-associated kaposi's sarcoma by radiotherapy